Epicorticosterone

Epicorticosterone

SCHEMBL15920519

C[C@]12C[C@H](O)C3C(CCC4=CC(=O)CC[C@@]43C)C1CCC2C(=O)CO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 1.00
HIF1A Q16665 6/20 1.00
NR3C2 P08235 6/20 1.00
LMNA P02545 4/20 1.00
SHBG P04278 4/20 1.00
SERPINA6 P08185 4/20 1.00
HSD17B10 Q99714 4/20 1.00
CYP3A4 P08684 4/20 1.00
MAPT P10636 3/20 1.00
MAPK1 P28482 2/20 1.00
NFKB1 P19838 2/20 1.00
BLM P54132 1/20 1.00
CYP2C9 P11712 1/20 1.00
TSHR P16473 1/20 1.00
SLC22A2 O15244 1/20 1.00
SLC22A1 O15245 1/20 1.00
SLC22A3 O75751 1/20 1.00
THPO P40225 1/20 1.00
MTOR P42345 1/20 1.00
SIGMAR1 Q99720 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Epicorticosterone SCHEMBL19465689 1.00 SMN1; SMN2 (1.00) SMN1; SMN2HIF1ANR3C2LMNASHBG
Corticosterone SCHEMBL22612 1.00 SMN1; SMN2 (1.00) SMN1; SMN2HIF1ANR3C2LMNASHBG
Epicorticosterone SCHEMBL14592717 1.00 SMN1; SMN2 (1.00) SMN1; SMN2HIF1ANR3C2LMNASHBG
Epicorticosterone SCHEMBL17287012 1.00 SMN1; SMN2 (1.00) SMN1; SMN2HIF1ANR3C2LMNASHBG
Corticosterone SCHEMBL5669349 1.00 SMN1; SMN2 (1.00) SMN1; SMN2HIF1ANR3C2LMNASHBG
Epicorticosterone SCHEMBL4380327 1.00 SMN1; SMN2 (1.00) SMN1; SMN2HIF1ANR3C2LMNASHBG
Epicorticosterone SCHEMBL20058459 1.00 SMN1; SMN2 (1.00) SMN1; SMN2HIF1ANR3C2LMNASHBG
Epicorticosterone SCHEMBL9070639 1.00 SMN1; SMN2 (1.00) SMN1; SMN2HIF1ANR3C2LMNASHBG
Epicorticosterone SCHEMBL21168995 1.00 SMN1; SMN2 (1.00) SMN1; SMN2HIF1ANR3C2LMNASHBG
Epicorticosterone SCHEMBL20242898 1.00 SMN1; SMN2 (1.00) SMN1; SMN2HIF1ANR3C2LMNASHBG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112552364-A Novel 11 beta-hydroxysteroid compounds for use in mitochondrial biogenesis and diseases associated with mitochondrial dysfunction or depletion 司菲埃拉制药私人有限公司 2021-03-26 CN claimed
EP-3309166-A2 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION Sphaera Pharma Pvt. Ltd. (IN) 2018-04-18 EP claimed
US-20150376225-A1 NOVEL COMPOUNDS OF 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION EPIRIUM BIO INC. 2015-12-31 US claimed
US-20240270786-A1 STEROID COMPOUNDS EPIRIUM BIO INC (US) 2024-08-15 US disclosed
CN-112552364-A Novel 11 beta-hydroxysteroid compounds for use in mitochondrial biogenesis and diseases associated with mitochondrial dysfunction or depletion 司菲埃拉制药私人有限公司 2021-03-26 CN disclosed
EP-3309166-A2 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION Sphaera Pharma Pvt. Ltd. (IN) 2018-04-18 EP disclosed
EP-3309166-A2 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION Sphaera Pharma Pvt. Ltd. (IN) 2018-04-18 EP disclosed
US-20150376225-A1 NOVEL COMPOUNDS OF 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION EPIRIUM BIO INC. 2015-12-31 US disclosed
US-20150376225-A1 NOVEL COMPOUNDS OF 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION EPIRIUM BIO INC. 2015-12-31 US disclosed
US-20150376225-A1 NOVEL COMPOUNDS OF 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION EPIRIUM BIO INC. 2015-12-31 US disclosed
WO-2014115167-A2 NOVEL COMPOUNDS OF 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION SPHAERA PHARMA PVT. LTD. (IN) 2014-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240270786-A1 STEROID COMPOUNDS NR5A1, NR3C2, CYP17A1 SMN1; SMN2 1751/4885HIF1A 4641/4885NR3C2 2/4885
US-20150376225-A1 NOVEL COMPOUNDS OF 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION CYP27A1, CYP27B1, TFAM SMN1; SMN2 623/4885HIF1A 446/4885NR3C2 285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.